Jennifer Gordetsky, MD Professor, Medical Director of Anatomic Pathology Departments of Pathology, Microbiology, and Immunology; Urology Vanderbilt University Medical Center Objectives: - Understand the new recommendations for reporting cancer on MRI-Targeted prostate biopsy.
- Recognize the established and emerging prognostic histologic findings on prostate pathology.
- Compare the similarities and differences between intraductal carcinoma of the prostate and invasive cribriform cancer.
- Recognize the limitations of reporting the percent of Gleason pattern 4 prostate cancer in biopsies with Grade Group 2 tumors.
Speaker disclosures: Dr. Jennifer Gordetsky discloses a financial relationship with Janssen Research and Development [consultant] within the past 24 months. All conflicts of interest have been mitigated. Why Attend? Prostate cancer makes up 1 in 5 new cancer diagnoses in men. In the United States, there is estimated to be over 260,000 new prostate cancer cases and 34,500 deaths due to this disease in the last year. While the early detection of prostate cancer remains an important step in preventing cancer related deaths, many patients diagnosed with prostate cancer will die of other causes. Thus, it is equally important to determine the biologic potential of each individual’s tumor. New techniques such as multiparametric MRI of the prostate and MRI-targeted biopsy have improved the detection and diagnosis of clinically significant prostate cancer. At the same time, new recommendations in the reporting of prostate cancer grade, morphology, and other histologic findings on prostate biopsy have helped guide clinicians in terms of choosing active surveillance versus recommending definitive therapy. This presentation addresses recent advances in the detection of prostate cancer and recommendations for the reporting of established and emerging prognostic markers in prostate pathology. Meeting ID: 983 8715 9855 Passcode: PATHGR You must sign-in on the following form to receive CME credit. Sign-in online: https://forms.gle/W2oE8d3MYbnyTDe58
Planning Committee Disclosure: The following members have not had any financial relationships with any ineligible entities in the past 24 months: Drs. Rebecca Alvarez, Eleanor Chen, Austin Green, Jose Mantilla, Isaac Miller, Elizabeth Parker, Maria Tretiakova, and Larry True. The following members disclose financial relations with ineligible entities within the past 24 months: Dr Shreeram Akilesh GoldfinchBio, Inc. (sponsored research) and NanoString, Inc. (sponsored travel); and Dr. Haodong Xu PathomIQ (consultant). All relevant financial relationships listed have been mitigated.
Grant Acknowledgment: None
CME Accreditation statement: The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Washington School of Medicine designates this live activity for a maximum of 10.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. (Each session is 1.0 credit) |